AbbVie (NYSE: ABBV), which completed the acquisition of Allergan on May 8, 2020, reported second quarter 2020 earnings results today. The company’s adjusted earnings and revenue in Q2 bettered the market’s estimates. which included a partial quarter of Allergan and COVID-19 pandemic impact.
ABBV stock was trading up about 2% in the before market hours.
On an adjusted basis, earnings increased to $2.34 per share from $2.26 per share in the year-ago quarter. On a GAAP basis, AbbVie posted a loss of $0.46 per share compared to a profit of $0.49 per share in the second quarter of 2019.
Revenues of $10.425 billion, increased 26.3% on a reported basis, and decreased 5.3% on a comparable operational basis, due to the COVID-19 pandemic.
AbbVie provided combined company earnings outlook for fiscal 2020, which includes the results of Allergan from May 8, 2020 through December 31, 2020. The company now expects GAAP EPS to be in the range of $4.12 to $4.22. On a non-GAAP basis, profit is now expected to be in the range of $10.35 to $10.45 per share.
The retail environment has witnessed many changes in customers’ shopping behavior lately, especially after the COVID outbreak. With inflation putting pressure on personal finances, there appears to be a new
Shares of Dollar General Corporation (NYSE: DG) were up over 2% on Friday, a day after the company delivered mixed results for the third quarter of 2022 and lowered its
For technology stocks, 2022 has been a challenging year, with companies losing significant market value amid prolonged stock selloff. In that respect, Salesforce, Inc. (NYSE: CRM) is among the worst-affected